Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection

Abstract

The combination of raltegravir, ETR, and DRV/r was a highly effective and well-tolerated antiretroviral salvage regimen in patients infected with multidrug-resistant HIV-1.

Optimized Antiretroviral Therapy with Darunavir/Ritonavir, Etravirine and/or Raltegarvir: A Salvage Therapy Option in HIV-1 Infected Patients with Long-Term Therapeutic Failures, about 23 Cases

“…This viral load suppression was remarkable for patients infected with HIV-1 that has triple-class drug resistance and in whom therapy had failed previously. As observed in our study, the efficiency of darunavir, etravirine and raltegravir in MDR HIV-1 infected patients has been previously reported [8,15]. It has been shown that in patients infected by MDR HIV-1 with few remaining treatment options, the optimized background therapy combined with these new molecules had a rapid and potent antiretroviral effect that was superior to the effect of optimized background therapy [8,15].…”

“…The difficult-to-treat-patients developing MDR HIV infection have high experience with antiretroviral therapy and no therapeutic option with all disposed antiretroviral drugs was possible. Recently, three molecules, darunavir/ritonavir, etravirine and ralté-gravir were proposed in the treatment of HIV infected patients [6][7][8][9][10][11][12][13][14][15]. In this study, we analyzed the efficiency of these new drugs combined to optimized background therapy during twelve months in patients with advanced MDR HIV-1 infection and treatment failures with the three classes of antiretroviral drugs.…”

“…Although phase 3 clinical studies with each of these individual new antiretrovirals have demonstrated their potential as salvage therapy, there is limited experience for the combination of these 3 antiretrovirals in patients with MDR HIV-1 [8][9][10][11][12][13][14][15].…”

Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 Weeks

“…The observation of lower rates of adverse events in the DRV/r and PI-Sparing treatment strategies echo the favorable safety profiles for post-2006 treatment options reported in recent clinical trials. [2][3][4][6][7][8][9][10][11][12] The results of this study should be interpreted within the context of its limitations. As a single academic HIV clinic in the Southeastern USA, results may not be generalizable to other locations.…”

“…With various clinical trials highlighting the safety and superior efficacy of these newer agents, complete virologic suppression has become the therapeutic goal for all HIV-infected patients, including those who are treatment-experienced. [1][2][3][4][5][6][7][8][9][10][11][12] Despite the accumulating body of evidence from clinical trials, a paucity of published data addressing the effectiveness of these newer agents in routine clinical care settings exists. Evaluating both the efficacy and effectiveness of newer agents is important to ensure that the results obtained from clinical trials are generalizable to populations treated through routine care.…”